Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep synergizes with azacitidine

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Jul 25, 2023 10:15am

201 Views

Post# 35555740

RE:Pelareorep synergizes with azacitidine

I noticed Immugene was mentioned on another site. Perhaps it is of interest to note that Dr. Laeufle who was closely involved with the GOBLET design, left ONC/Y to work for a time at Immugene. It is not too much of a stretch to imagine that she was aiding and advising pharma on oncolytic viruses. That is just idle speculation on my part. The excellent design of GOBLET is not.

We shall patiently wait for the inevitable.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec